Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study

Takashi Iizuka; Kotaro Iemitsu; Masahiro Takihata; Masahiko Takai; Shigeru Nakajima; Nobuaki Minami; Shinichi Umezawa; Akira Kanamori; Hiroshi Takeda; Takehiro Kawata; Shogo Ito; Taisuke Kikuchi; Hikaru Amemiya; Mizuki Kaneshiro; Atsuko Mokubo; Tetsuo Takuma; Hideo Machimura; Keiji Tanaka; Taro Asakura; Akira Kubota; Sachio Aoyagi; Kazuhiko Hoshino; Masashi Ishikawa; Yoko Matsuzawa; Mitsuo Obana; Nobuo Sasai; Hideaki Kaneshige; Fuyuki Minagawa; Tatsuya Saito; Kazuaki Shinoda; Masaaki Miyakawa; Yasushi Tanaka; Yasuo Terauchi; Ikuro Matsuba

doi:10.14740/jocmr.v8i3.2510

J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Correction

Volume 8, Number 3, March 2016, pages 267-267

Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study

Takashi Iizuka^a, Kotaro Iemitsu^a, Masahiro Takihata^a, Masahiko Takai^a, Shigeru Nakajima^a, Nobuaki Minami^a, Shinichi Umezawa^a, Akira Kanamori^a, Hiroshi Takeda^a, Takehiro Kawata^a, Shogo Ito^a, Taisuke Kikuchi^a, Hikaru Amemiya^a, Mizuki Kaneshiro^a, Atsuko Mokubo^a, Tetsuo Takuma^a, Hideo Machimura^a, Keiji Tanaka^a, Taro Asakura^a, Akira Kubota^a, Sachio Aoyagi^a, Kazuhiko Hoshino^a, Masashi Ishikawa^a, Yoko Matsuzawa^a, Mitsuo Obana^a, Nobuo Sasai^a, Hideaki Kaneshige^a, Fuyuki Minagawa^a, Tatsuya Saito^a, Kazuaki Shinoda^a, Masaaki Miyakawa^a, Yasushi Tanaka^{a, b}, Yasuo Terauchi^c, Ikuro Matsuba^{a, d}

^aStudy Group of the Diabetes Committee, Kanagawa Physicians Association, Kanagawa, Japan
^bDivision of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan
^cDepartment of Endocrinology and Diabetes, Yokohama City University Medical Center, Kanagawa, Japan
^dCorresponding Author: Ikuro Matsuba, Matsuba Medical Clinic, 2-159 Tsukagoshi, Saiwai-ku, Kawasaki-shi, Kanagawa 212-0024, Japan

Manuscript accepted for publication January 20, 2016
Short title: Efficacy and Safety of Ipragliflozin
doi: http://dx.doi.org/10.14740/jocmr2417wc1

Corrections to article “Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study”, by Takashi Iizuka et al, published in Vol. 8, No. 2, 2016, p116-125, doi: http://dx.doi.org/10.14740/jocmr2417w

There were some errors in Table 2, the authors would like to make the following corrections.
The baseline postprandial blood glucose level (mg/dL) should read 199.1 ± 85.2, instead of 199.1 ± 1.49.
The 12 weeks postprandial blood glucose level (mg/dL) should read 154.9 ± 60.5, instead of 54.9 ± 60.5.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Journal of Clinical Medicine Research is published by Elmer Press Inc.

QUICK LINKS
	Instructions to Authors
	Editorial Board
	Publication Ethics
	Human & Animal Rights
	Informed Consent
	Conflict of Interest
	Copyright and Permission
	Journal Contact
	Publishing Charge

Username
Password
Remember me

Journals | Policy | Permission Journal of Clinical Medicine Research

Journals | Policy | Permission

Journal of Clinical Medicine Research